Breast cancer is a leading cause of death for women in industrialised countries with a 10% lifetime risk of disease and over 1 million new cases annually. The oestrogen receptor positive (ER+) breast cancers suppose the 80% of all breast cancers. Despite the success of anti-estrogenic therapies, resistance still appears in patients and constitute the main obstacle in their management. Although the molecular mechanisms behind anti-oestrogen resistance are yet to be fully elucidated, evidences link treatment resistance with activation of the nuclear factor-*κ*B (NF-*κ*B) pathway ([@bib54]). Moreover, NF-*κ*B affects ER expression and activity in breast cancer through multiple mechanisms ([@bib41]).

NF-*κ*B transcription factors are either homodimers or heterodimers of five proteins: RelA, c-Rel, RelB, NF-*κ*B2 (p52) and p50 and they are tightly regulated. In unstimulated normal cells, inactive NF-*κ*B exists in the cytoplasm bound to inhibitory proteins. The phosphorylation and degradation of the inhibitory molecule that is induced by a specific signal causes the subsequent release and nuclear shuttling of NF-*κ*B dimers to induce the expression of genes. Each NF-*κ*B dimer selectively regulates a set of target genes involved in cell proliferation and survival, inflammation and innate immunity ([@bib40]). In tumour tissues, NF-*κ*B signalling pathway is constitutively active ([@bib4]) and has been implied in tumorogenesis and resistance mechanisms towards treatment ([@bib2]; [@bib22]; [@bib37]).

There are two major NF-*κ*B activation pathways, the canonical and the non-canonical that differ by the stimuli that activate them, the kinases complexes implicated as well as the inhibitory NF-*κ*B proteins. The canonical pathway used mainly p65 and p50 subunits, and I*κ*Bs as inhibitory protein. Instead, the non-canonical pathway involves NF-*κ*B2 and RelB subunits, and the NF-*κ*B-inducing kinase (NIK) and IKK*α* kinases. RelB is synthetised in mature form ([@bib29]) and NF-*κ*B2 as a precursor form named p100, which also function as I*κ*B-like molecules ([@bib31]). As p100 preferentially interacts with RelB ([@bib17]; [@bib42]), the processing of p100 not only generates NF-*κ*B2 but also causes NF-*κ*B2/RelB translocation ([@bib44]) and regulation of responsive target genes ([@bib49]).

The vast majority of studies on NF-*κ*B in cancer have focused on p65 and p50 subunits and little information about the non-canonical pathway activity is available. The purpose of this study was to evaluate the implication of NF-*κ*B2 and RelB subunits in ER+ breast cancer patients using tumour samples from two cohorts of patients that were analysed either by DNA-binding ELISA or immunohistochemistry. We have also aimed to correlate non-canonical NF-*κ*B activation with clinico-pathological characteristics and to evaluate their potential prognostic significance.

Materials and methods
=====================

Clinical samples
----------------

The training cohort included fresh-frozen tissues specimens (*n*=121) obtained from chemo-naive surgically resected ER+ breast cancer patients and diagnosed in the Hospital Clínico de Valencia. During surgery, tumour fragments were collected in sterile containers, frozen and stored at −80°C. Samples of 15 ER− breast cancer patients were also included in the study. The clinico-pathological characteristics of these breast tissues are summarised in [Table 1](#tbl1){ref-type="table"}. The validation cohort included formalin-fixed paraffin-embedded (FFPE) tissues of 207 ER+ breast cancer patients from Biobanks of Hospital del Mar (Barcelona), Fundación Jimenez Diaz (Madrid) and Hospital Clinico de Valencia/INCLIVA, treated with tamoxifen. The clinico-pathological characteristics of these samples are summarised in [Table 2](#tbl2){ref-type="table"}. The study was approved by the Institutional Ethics Committee of the three institutions and all subjects gave written informed consent to enter into the study.

Tissue quality determination and tissue microarray construction
---------------------------------------------------------------

Frozen tissues were embedded in optimal cutting temperature compound and sectioned at a 10-*μ*m thickness with a cryostat, mounted onto microscope slides and stained with haematoxylin and eosin. Stained sections of the cases were reviewed, and the areas of the tumour were marked on the slides. Samples that contained more than 70% malignant cells were selected for inclusion in the study. From each FFPE tissue block, three tumour representative cores (1 mm in diameter) were sampled from each marked area in the donor block and mounted on a recipient paraffin block using a TMA workstation (T1000 Chemicon/Merck Millipore, Temecula, CA, USA), as previously described ([@bib39]).

Determination of NF-*κ*B subunits activation by immunohistochemistry
--------------------------------------------------------------------

Four microns tissue sections from TMAs were placed on plus charged glass slides. After deparaffinization, heat antigen retrieval was performed in pH9 EDTA-based buffer (Dako, Carpinteria, CA, USA). Endogenous peroxidase was blocked and slides were incubated with primary antibodies previously described by us ([@bib45]) to NF-*κ*B2 (K27, SC298) and RelB (C19, SC226), both from Santa Cruz Biotechnologies (Dallas, TX, USA) for 60 min, followed by appropriate anti-Ig horseradish peroxidase-conjugated polymer (Flex+, Dako) using a Dako Autostainer, and visualised with 3,3′-diaminobenzidine. Sections incubated with non-immunised serum were used as negative controls and breast tumours with a known expression of markers were used as positive control ([@bib45]). The interpretation of immunohistochemical staining was based on the percentage and intensity of the immunoreactive tumour cells with nuclear expression of markers in each core, and the final values of the positive tumour cells were evaluated as the mean of the immunoreactivity in three cores. The staining intensity was visually scored and stratified as follows: 0 (negative), 1 (weak, if it was a blush), 2 (intermediate) and 3 (strong staining). A semiquantitative HistoScore (H-score) was calculated by estimation of the percentage of tumour cells positively stained with low, medium or high staining intensity. The final score was determined after applying a weighting factor to each estimate. The following formula was used: H-score=(low%) × 1+(medium%) × 2+(high%) × 3 and the results ranged from 0 to 300. All of the slides were evaluated independently by two experienced pathologists (FR and JF) blinded to clinico-pathological data. Expression cutoffs for each marker was defined using ROC curves.

Determination of DNA-binding activity of NF-*κ*B subunits
---------------------------------------------------------

Nuclear protein extracts were obtained from frozen breast cancer tissue using Nuclear Extract Kit (Active Motif, Carlsbad, CA, USA) according to the manufacturer\'s instructions. The protein concentration was determined using Bradford Reagent assay (Sigma-Aldrich, St Louis, MO, USA). NF-*κ*B activity was measured in nuclear protein extracts by the TransAM NF-*κ*B Kit (Active Motif), an ELISA-based method designed to specifically detect and quantify NF-*κ*B subunits activation, with high sensitivity and reproducibility.

Briefly, the NF-*κ*B TransAM kit contains a 96-well plate with immobilised oligonucleotides containing the NF-*κ*B consensus (5′-GGGACTTTCC-3′) sequence for NF-*κ*B. Nuclear extracts are added to each well and the active form of NF-*κ*B that is present in the extract binds specifically to the oligonucleotide coated on the plate. Then specific antibodies for the activated forms of NF-*κ*B2 and RelB subunits of NF-*κ*B are added. These antibodies recognise epitopes on either NF-*κ*B2 or RelB that are accessible only when NF-*κ*B is activated and bound to its target DNA. A secondary horseradish peroxidase (HRP)-conjugated antibody and chromogenic substrate is added. Colorimetric readout is quantified by spectrophotometry at 450 nm with a reference wavelength of 655 nm. DNA-binding specificity was assessed by competition assays using NF-*κ*B wild type and mutated consensus oligonucleotides. The median value of the analysed tumours for each subunit was taken as cutoff of activation.

Immunofluorescence staining of human breast carcinomas
------------------------------------------------------

Immunofluorescence analysis of RelB and NF-*κ*B2 was performed on two sequential formalin-fixed paraffin-embedded 3 *μ*m tissue sections from breast carcinoma specimens placed on positively charged glass slides (two per specimen) according to our previous experience ([@bib45]). After deparaffinization, antigen retrieval was performed by incubation in Tris-EDTA buffer, pH 9.0 (Dako), in a heated (97 °C) water bath for 40 min. The tumour sections were immersed in TBS/5% BSA for 10 min to block non-specific binding. For co-localisation experiments on the same cells, double immunofluorescence techniques were used. Formalin-fixed paraffin-embedded samples were incubated with a mixture of anti-NF-*κ*B2 rabbit (1 : 100 dilution), anti-RelB mouse (1 : 200 dilution) and anti-ER mouse (clone 1D5, 1 : 1 dilution, Dako) and rabbit (clone SP1, 1 : 1 dilution, Ventana, Tucson, AZ, USA) antibodies. Secondary detection antibodies were Alexa 488 coupled goat antirabbit IgG and Alexa 555 coupled goat antimouse IgG (1 : 1000 dilutions) (Lifetechnologies, Grand Island, NY, USA) generating green fluorescence and red fluorescence for polyclonal and monoclonal antibodies, respectively. Sections were counterstained with 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI, Vysis, Downers Grove, IL, USA) to visualise cell nuclei. All incubations were performed at room temperature. Fluorescence assays were performed using a Dako Autostainer. Staining was evaluated by a pathologist (FR) using a Leica fluorescence DM2000 microscope. Pictures were obtained by Leica Application Suite v2.8.1 and colour deconvolution and image composition was performed using ImageJ software (<http://rsb.info.nih.gov/ij>).

*In silico* data analysis of publicly available genomic data sets related to breast cancer
------------------------------------------------------------------------------------------

Normalised expression (RNA-seq RPKMs) data of breast tumours in the TCGA cohort and clinical data of patients of the same cohort were downloaded from synapse (syn300013) and TCGA Data Portal (<https://tcga-data.nci.nih.gov/tcga/>), respectively. These data were used for the analysis of the expression levels of RelB and NF-*κ*B2 genes in both ER− and ER+ breast tumours. The expression and clinical data of breast cancer patients in the GSE3494 data set (PMC1197273), that includes a total of 251 tumours ([@bib28]) were downloaded from the GEO data repository ([@bib14]). These data were exploited to build prediction models for ER+ patient\'s survival using NF-*κ*B-driven selected genes. The expression data of the latter data set was gene-wise mean-centred before the analysis.

Statistical analysis
--------------------

Statistical analysis was carried out with the program SPSS version 22.0 (SPSS, Inc., Chicago, IL, USA). Receiver operating curve (ROC) was used to determine the optimal cutoff point based on relapse endpoint for RelB and NF-*κ*B2 expression by immunohistochemistry. To analyse correlations between NF-*κ*B2 and RelB expression and clinico-pathological variables we used *χ*^2^ test (Fisher exact test), based on bimodal distribution of data. Disease-free survival (DFS) was considered from date of diagnosis to date of any primary, regional or distant recurrence of the infiltrating carcinoma, as well as appearance of a secondary tumour or death. Overall survival (OS) was defined as the time from the date of surgery to the date of death from any cause or last follow-up. Univariate analysis for DFS and OS curves were constructed based on Kaplan--Meier life-table method and analysed using log-rank test of equality. Multivariate survival analysis was calculated using Cox proportion model. Graphical summaries of the distributions were made using boxplots. All the statistical tests were conducted at two sided 0.05 level of significance. This work was carried out in accordance with Reporting Recommendations for Tumour Marker Prognostic Studies (REMARK) guidelines.

Results
=======

Non-canonical NF-*κ*B pathway is activated in ER+ breast cancer with low expression of the oestrogen receptor gene
------------------------------------------------------------------------------------------------------------------

We assessed the involvement of RelB and NF-*κ*B2 in ER+ breast cancer. Very few studies have analysed NF-*κ*B non-canonical pathway and breast cancer ([@bib50]), demonstrating only an inverse correlation between RelB and ER mRNA expression based on publicly available data. Because NF-*κ*B acts as a dimer, we decided to recapitulate whether the levels of expression of both *RelB* and *NF-κB2* genes correlate with the ER gene (*ESR1)* expression in breast tumours. To that end, we obtained normalised RNA-seq data of tumours in the breast cancer TCGA cohort from synapse (syn300013) and clinical data of the patients in this cohort from the TCGA Data Portal<https://tcga-data.nci.nih.gov/tcga/>. RNA-seq data and clinical annotations were then merged by mapping patients and tumours barcodes. According to the clinical observations, the cohort included 489 ER+ and 177 ER− breast tumour samples with expression data for comparison. The 489 ER+ tumours were further divided in four subsets corresponding to the quartiles of gene expression of *ESR1*. Our analysis confirmed that RelB mRNA levels correlate inversely with ER status in primary breast cancer (*P*\<0.001). Moreover, detailed quartile-based analysis of expression level showed an inverse association between ER and RelB expression levels (*P*\<0.001) supporting that low ER+ tumours have a phenotype more similar to the ER− breast cancer. This behaviour is also true for NF-*κ*B2 mRNA in human primary breast cancers (*P*\<0.001 for both subunits) ([Figure 1](#fig1){ref-type="fig"}).

Because these data is at gene expression level, we decided to explore whether differences on RelB and NF-*κ*B2 protein activation does exist between ER− and ER+ patients. For this analytical validation, we used an available set of fresh-frozen breast tissues of 121 ER+ and 15 ER− breast cancer patients blinded to clinical data. We analysed nuclear extracts prepared by a commercial ELISA-like assay for detecting DNA-binding activity of NF-*κ*B. Demographic data of the patients are shown in [Table 1](#tbl1){ref-type="table"}. Box plot in [Figure 2](#fig2){ref-type="fig"} shows that RelB and NF-*κ*B2 are active in similar percentages in ER- and ER+ tumours (53.7% NF-*κ*B2 activation in ER+ and 60% in ER-; 49.2% RelB activation in ER+ and 50% in ER-). In these series, no significant correlation was found between RelB or NF-*κ*B2 activation and clinico-pathological characteristics of the patients at the time of diagnosis, including age, tumour size, nodal status, histological type and histological grade (data not shown).

Because of these results, we then plan to study in more detail the clinical consequences of the non-canonical NF-*κ*B pathway activation in ER+ breast cancer. For that, we use a second larger cohort (*n*=207) of ER+ breast cancer patients with clinical follow-up, assaying RelB and NF-*κ*B2 expression by IHC on FFPE tumour samples. Demographic and clinical characteristics of the patients are shown in [Table 2](#tbl2){ref-type="table"}. RelB and NF-*κ*B2 subunits were present diffusely in the cytoplasm and in a proportion of nuclei of neoplastic cells, homogeneously distributed in tumours. Weak expression was also detected in the nucleus of some stromal cells, including fibroblasts and lymphocytes ([Figure 3A](#fig3){ref-type="fig"}). This nuclear expression of RelB was present in 108 (32.4%) breast tumours, and NF-*κ*B2 in 124 (59.9%) cases. In tumours with detected nuclear expression of NF-*κ*B2 and RelB, multiplexing immunofluorescence confirmed the significant co-localisation of both subunits up to 73% of tumour cells ([Figure 3B](#fig3){ref-type="fig"}) (*P*=0.002); only 9% of cells expressed only RelB and 11% of cells, only NF-*κ*B2 subunit. Accordingly to previous results, we attempted to correlate the ER expression levels by immunohistochemistry with the nuclear detection of NF-*κ*B2 and RelB in breast tumours. Considering those tumour samples (184 from the total of 207) from which the information of % of cells expressing ER was available, we divided into quartiles the cohort ([Figure 3C](#fig3){ref-type="fig"}). The ER expression was inversely correlated with the expression in the nucleus of RelB and NF-*κ*B2 (*P*\<0.001). Finally, multiplexing immunofluorescence for ER, NF-*κ*B2 and RelB determined an inverse spatial distribution of ER and NF-*κ*B2, and ER and RelB nuclear expression in tumour cells ([Figure 3D](#fig3){ref-type="fig"}), detecting lower expression or absence of ER in tumour cells with detectable NF-*κ*B2 and RelB nuclear expression.

In this second cohort of breast cancer patients, we detected associations between nuclear NF-*κ*B2 expression with lymph node involvement (*P*=0.028) and relapse of the disease (*P*=0.022). In addition, RelB nuclear expression was correlated with relapse (*P*=0.038). Finally, the co-expression of RelB and NF-*κ*B2 in breast tumours was correlated with relapse (*P*=0.015). No additional significant correlations were found between RelB or NF-*κ*B2 and the rest of clinico-pathological variables analysed (data not shown).

NF-*κ*B2 and RelB activation are associated with poor prognosis in ER+ breast cancer
------------------------------------------------------------------------------------

Then, we investigate the association between activation of NF-*κ*B2 and RelB subunits in tumour cells and the outcome of the patients ([Figure 4A](#fig4){ref-type="fig"}). In these series, nuclear NF-*κ*B2 and expression correlated with DFS (*P*=0.005, HR=2.1, 95% CI: 0.9--4.5) and a trend towards worse OS (*P*=0.056, HR=2.3, 95% CI: 0.7--8.1) in ER+ population. As expected, nuclear RelB expression was also associated with DFS (*P*=0.035, HR=2.1, 95% CI: 1.1--4.1) and a trend towards worse OS (*P*=0.078, HR=1.6, 95% CI: 0.7--4.2) in same patients. Supporting these data, we analysed the prognosis of the co-expression of RelB and NF-*κ*B2 in ER+ breast cancer patients ([Figure 4B](#fig4){ref-type="fig"}). The presence of both subunits strongly correlated with DFS (*P*=0.002, HR=2.8, 95% CI: 1.2--6.7) and OS (*P*=0.001, HR=2.4, 95% CI: 0.8--7.3).

Finally, in the multivariate survival analysis, RelB and NF-*κ*B2 co-expression in ER+ tumours samples retained this significant association with worse DFS (*P*=0.005, HR=5.5, 95% CI: 1.6--15.8) and OS (*P*=0.018, HR=4.8, 95% CI: 1.1--12.1) in ER+ breast cancer cases. This association is deeply related to patients survival that each subunit separately suggesting that the heterodimer NF-*κ*B2/RelB is more important in the response to treatment that the formation of the homodimers.

NF-*κ*B2 /RelB expression, target gene expressions and clinical outcomes
------------------------------------------------------------------------

Our data results related the activation of the heterodimer RelB/NF-*κ*B2 with poor survival in the subgroup of breast cancer patients with ER positivity. In order to go further and to analyse whether we could found not only a prognostic significance of nuclear NF-*κ*B2 and RelB but also of its target gene products in ER+ breast cancer patients. We exploited bioinformatics to evaluate the correlation between *NF-κB2* and *RelB* gene expression and survival in ER+ patients from public databases. For our studies, we selected those genes whose levels correlated with the levels of NF-*κ*B2 and RelB of RE+ in the GSE3494 data set (PMC1197273) and data set ([@bib28]) from the published target genes of NF-*κ*B ([@bib36]). Among the genes analysed, we found that the expression of the *myoglobin* (*MB*) gene (NM_203377) was coherent with RelB expression values (*P*-value\<0.01), and confirmed that *MB* gene expression was associated in the same way to poor outcome in ER+ breast cancer patients ([Figure 5](#fig5){ref-type="fig"}). In tumour samples, the expression (mRNA) of *MB* was not significantly coherent with those of nor p50 subunits (Rel A: *P*-value=0.39; p50: *P*-value=0.07). Although it is known that extensive cross-regulation between the canonical and non-canonical signalling axes seems to exist ([@bib8]), a recent work reinforces the idea of MB as a possible surrogate of the activation of the non-canonical NF-*κ*B pathway ([@bib23]). This study provides gene expression data (GSE30670) on MDA-MB-231 cells with Rel A or RelB depletion achieved by siRNA transfection. MB gene was downregulated by the down-regulation of RelB, and did not change by the down-regulation of RelA. Overall we have assumed that MB depends on RelB and discriminates between ER+ patients.

Discussion
==========

Approximately 80% of breast cancers express ER. Once activated by 17B-estradiol, ER dimerises and translocates into the nucleus where it binds to DNA and regulates the expression of different target genes ([@bib27]). The administration of endocrine therapy targeting ER has significantly improved the survival in ER+ breast cancer patients ([@bib13]). However, efficacy of endocrine therapy is limited by initial *de novo* and acquired resistance mechanisms, including the deregulation of components of the ER pathway, changes in the expression or action of the ER itself ([@bib53]), alterations in cell cycle by maintained/high cyclin-D1 and cyclin-E1 expression, alterations in survival signalling molecules, or adaptive upregulation of alternate signalling pathways ([@bib18]). However, definition of the specific genetic lesions and molecular processes that determine clinical endocrine resistance is incomplete ([@bib32]; [@bib46]) and therefore candidate molecular biomarkers of endocrine response are not yet available. Another signal transduction pathway that might contribute to the development of endocrine resistance is NF-*κ*B. A regulated activation pattern of NF-*κ*B pathway is essential for normal development of the mammary gland, but an aberrant constant increase in NF-*κ*B activity is implicated in breast cancer. NF-*κ*B is able to affect ER pathway by multiple and complex mechanisms ([@bib41]; [@bib52]; [@bib34]), including downregulation of ER expression ([@bib16]). Several studies have demonstrated an inverse correlation between ER expression and NF-*κ*B pathway ([@bib33]; [@bib7]; [@bib47]), supporting a predominant NF-*κ*B activation in ER− breast cancer ([@bib6]). In addition, using publicly available gene expression data, a highly significant negative correlation between a gene NF-*κ*B activation signature expression ([@bib1]) and the ER activity has been demonstrated ([@bib41]). Similarly, the levels of NF-*κ*B DNA binding ([@bib54]) or the expression of target genes ([@bib48]) are also inversely correlated with ER expression. Association between ER levels and the risk of recurrence exists ([@bib21]), and the ability of NF-*κ*B to repress ER might be clinically relevant. However, this clinical significance of NF-*κ*B in breast cancer has been investigated mainly by studying p65 and p50 of the classical pathway. Constitutive NF-*κ*B has been observed in a subset of ER+ tumours that respond poorly to tamoxifen or aromatase inhibitors, and is associated with shortened DFS and increased metastatic recurrence ([@bib33]; [@bib55]; [@bib24]; [@bib26]). Then, the clinical relevance of non-canonical NF-*κ*B pathway represented mainly by NF-*κ*B2 and RelB subunits has been lest inquired ([@bib9]; [@bib50]). To our knowledge, no studies relating non-canonical NF-*κ*B pathway and survival in breast cancer have been reported.

Several studies have showed that heterogeneity exist within ER+ tumours. Our group and others have provided evidences that low ER+ tumours are more similar to the ER− than to usual ER+ tumours ([@bib8]; [@bib23]). Although the ASCO/CAP guidelines recommend that ER status should be considered positive if 1% or more of tumour cells demonstrate positive nuclear staining ([@bib20]), recent clinical data suggest that low expression of ER is associated with a downregulation of ESR1-associated gene signature and worse outcome, that is, highly ER-positive breast tumours ([@bib12]; [@bib38]). In fact, luminal B HER2-subtype is less responsive to endocrine therapy and is associated with poor survival ([@bib43]), exhibiting low expression of ER and ER-related genes compared with luminal A tumours ([@bib43]; [@bib11]).

In this work, in order to ascertain whether the non-canonical NF-*κ*B has a role in ER+ patient\'s outcome, we first based our analysis in mining public genomic databases, confirming that RelB and NF-*κ*B2 mRNA levels correlate inversely with ER status in primary breast cancer. An inverse correlation between constitutive RelB expression and ER has been described in breast ([@bib51]). The high RelB expression found in ER− tumours has been attributed in part to the fact that the ER signalling represses the RelB synthesis ([@bib50]). Moreover, RelB reciprocally inhibits ER synthesis by inducing the expression of a called Blimp1 protein that in turn mediates ER repression ([@bib51]). Nuclear expression of RelB is associated with more aggressive breast cancer ([@bib30]). Similarly, NF-*κ*B2 overexpression in mammary epithelium has been associated with tumorigenesis in animal models ([@bib10]), but have not shown apparent correlation with ER status in human breast tumours ([@bib9]). Then, we confirmed the non-canonical NF-*κ*B pathway activation, based on RelB and NF-*κ*B2 in a large cohort of ER+ breast cancer patients. Two methods were used to analyse both NF-*κ*B2 and RelB subunits activation in ER+ breast cancer, by a commercial ELISA assay, which has an immobilised oligonucleotide encoding an NF-*κ*B consensus site that only binds the active form of NF-*κ*B-specific subunit, and second, by evaluation of nuclear expression of NF-*κ*B2 and RelB subunits as a surrogate of activation by IHC. Non-canonical NF-*κ*B activation was independently associated with poor survival in ER+ breast cancer patients.

It is believed that non-canonical NF-*κ*B promotes a more invasive phenotype by induction of several genes and some authors suggest that resistance to therapy may proceed from the RelB promotes survival ([@bib30]). Among a list of reported NF-*κ*B genes ([@bib19]), we have found that overexpression of the *MB* gene is associated with worse survival in ER+ patients.Myoglobin is a cytoplasmic oxygen-binding hemoprotein that was thought to be solely present in both cardiac and skeletal muscle cells, and has a role in coping with chronic hypoxia. MB has been found to be overexpressed in a variety of cancers, including breast cancer, and seems to participate actively in carcinogenesis, although its role is not clear in tumour development and progression ([@bib15]; [@bib35]). Some studies have shown that MB expression correlated significantly with a positive ER alpha status and a better prognosis ([@bib25]), but it has been also suggested that solid tumours could take advantage of MB to manage with hypoxic environmental conditions associated with neoplastic growth ([@bib15]), confirmed by the description of co-expression of MB with markers of tumour hypoxia ([@bib5]), or that MB expression has been associated with worse outcome in NSCLC ([@bib35]).

Translational relevance
-----------------------

Conventional endocrine therapy is not always efficient in the treatment of ER+ breast cancer patients. There is not an efficient way to discriminate groups with different survival in ER+ breast cancer patients ([@bib3]) and predictive markers of response are needed. We explored the relationship between the activation of the non-canonical RelB and NF-*κ*B2 subunits, and the survival in this breast cancer subtype. Activation levels of NF-*κ*B2 and RelB predict outcome in ER+ breast cancer, but analysis of the co-expression more reliably predicts survival. Our findings suggest the activation of RelB and NF-*κ*B2 subunits as new predictive markers of response in ER+ breast cancers patients. Applications of this study are that increased expression of NF-*κ*B2 and RelB was associated with poor survival in ER+ breast cancer patients and MB expression in this subgroup of luminal tumours might be a surrogate marker of non-canonical NF-*κ*B2 pathway activation.
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![**Expression of NF-*κ*B2 and RelB mRNA in ER− and ER+ breast tumours from the TCGA cohort.** ER+ tumours are divided according to quartiles of expression of *ESR1*. The *Y*-axis shows arbitrary units.](bjc2016204f1){#fig1}

![**DNA-binding activity (activation) of NF-*κ*B2 and RelB proteins in ER+ and ER− breast tumours.** NF-*κ*B DNA binding for the two NF-*κ*B family members was evaluated using the ELISA-based TransAM NF-*κ*B Family kit (Active Motif). The read absorbance at 450 nm of lysis buffer added with the NF-*κ*B antibody dilution was used as blank to normalise the samples measure.](bjc2016204f2){#fig2}

![**Immunohistochemical staining for nuclear NF-*κ*B2 and RelB proteins expression in ER+ breast tumours.** (**A**) Representative image of breast cancer tissue sections with immunohistochemistry staining for RelB and NF-*κ*B2 proteins. Breast cancer cells evidence intense nuclear immunoreactivity for both NF-*κ*B family members. Images of random fields were taken at a magnification of × 100. Scale bars, 25 *μ*m. (**B**) Representative image of co-localisation RelB, and NF-*κ*B2 proteins by immunofluorescence. Sections were stained with antibodies against RelB (red) and NF-*κ*B2 (green); nuclei were visualised with DAPI (blue). Merged frames indicate co-localisation (yellow). Scale bars, 25 *μ*m. (**C**) Expression of NF-*κ*B2 and RelB protein in ER+ breast tumours according to expression levels of the receptor (*P*\<0.001). (**D**) Multiplexing immunofluorescence for ER and NF-*κ*B2, and for ER and RelB in sequential tissue sections. Scale bars, 25 *μ*m.](bjc2016204f3){#fig3}

![**DFS and OS curves for the NF-*κ*B2 and RelB groups in ER+ patients.** The Kaplan--Meier method was utilised to construct curves for DFS and OS according to the nuclear expression of each subunit (**A**) and the co-expression (**B**).](bjc2016204f4){#fig4}

![**DFS curve of RE+ breast patients according to the expression of *MB* gene.** dn=downregulated; up=upregulated.](bjc2016204f5){#fig5}

###### Characteristics of patients in training cohort

                         ***n*****=136**  
  --------------------- ----------------- -------
  Age (median, range)    56.72 (30--86)    
  Histology type                           
   Ductal                      100        73.53
   Lobular                     12         8.82
   Others                      15         11.03
   ND                           9         6.62
  Tumour grade                             
   I                            7         5.15
   II                          74         54.41
   III                         36         26.47
   IV                           9         6.62
   ND                          10         7.35
  Tumour size                              
   T0                           1         0.74
   T1                          19         13.97
   T2                          65         47.79
   T3                          17         12.50
   T4                          27         19.85
   ND                           7         5.15
  Lymph nodes                              
   N0                          37         27.21
   N1                          90         66.18
   N2                           3         2.21
   ND                           6         4.41
  ER status                                
   +                           121        88.97
   −                           15         11.03
  PGR status                               
   +                           111        81.62
   −                           25         18.38
  HER2 status                              
   +                           11         8.09
   −                           72         52.94
   ND                          53         38.97
  Menopausal status                        
   Post                        79         58.09
   Pre                         36         26.47
   Peri                         4         2.94
   ND                          17         12.50
  Treatment                                
   Anthracyclines              47         34.56
   Tamoxifen                   19         13.97
   Others                       2         1.47
   ND                          68         50.00

Abbreviations: ND=not determined; peri=perimenopausal; post=postmenopausal; pre=premenopausal.

###### Formalin-fixed paraffin-embedded validation cohort

                                  ***n*****=207**  
  ------------------------------ ----------------- ------
  Age (median, range)               57 (26--90)     
  Menopausal status                                 
   Premenopausal                        63         30.4
   Postmenopausal                       144        69.6
  Tumour size (mm)                                  
   ⩽20                                  127        61.4
   21--50                               65         31.4
   \>50                                 15         7.2
  Tumour grade                                      
   I                                    42         20.3
   II                                   107        51.7
   III                                  58         28.0
  Lymph nodes                                       
   None                                 126        60.9
   1--3                                 52         25.1
   4--9                                 17         8.2
   \>9                                  12         5.8
  Histology                                         
   Ductal                               189        91.3
   Lobular                              17         8.2
   Others                                1         0.5
  Progesterone receptor status                      
   Negative                             31         14.9
   Positive                             176        85.1
  Proliferation (Ki-67)                             
   Low proliferation (\<20%)            168        81.1
   High proliferation (⩾20%)            39         18.9
  Adjuvant chemotherapy                             
   No                                   45         21.7
   Yes                                  162        78.3
  Hormonotherapy                                    
   No                                   12         5.8
   Yes                                  195        94.2
  Relapse                                           
   No                                   180        86.9
   Yes                                  27         13.1

[^1]: Current address: University of Bergen, Norway.

[^2]: Current address: Pathology Department Hospital Universitario La Fe, Valencia, Spain.
